ReviewFrontiers in pharmacology2021
Nanoformulations of Ursolic Acid: A Modern Natural Anticancer Molecule.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 60 citations in OpenAlex.
- Ursolic acid: context-dependent redox activity on oxidative stress and its toxicological implications.Archives of toxicology · 2026Review
- One-pot synthesis of Mn/Fe bimetal-doped metal-organic framework as multifunctional nanocarriers for esophageal cancer targeted therapy.Journal of pharmaceutical analysis · 2026Article
- Ursolic Acid-fatty Acid Based Therapeutic Deep Eutectic Solvents: Response Surface Methodology Based Optimization and in vivo anti-microbial Effects against MRSA.Cell biochemistry and biophysics · 2026Article
- Stalling the Enemy: Targeting Nsp13 for Next-Generation SARS-CoV-2 Antivirals.International journal of molecular sciences · 2026Article
- Recent Advances in Smart Stimulus-Responsive Hydrogels for Precision Drug Delivery in Tumours.Gels (Basel, Switzerland) · 2026Review
- TRAIL of Hope: Bioactive Dietary Component-Driven Carrier-Free Nanoplatforms for Synergistically Enhanced Tumor Multimodal Therapy.International journal of nanomedicine · 2026Review
- Article
- Oral curative therapeutic study of N-nitrosodiethylamine-induced mouse liver damage of chitosan-coated ursolic acid niosomes.Scientific reports · 2025Article
- Ursonic Acid Ameliorates HMolecular neurobiology · 2025Article
- Phytochemical nanoencapsulation and microfluidics drive gene and tumor microenvironment modulation.Frontiers in pharmacology · 2025Review
- Nano-Based Drug Delivery Systems for Managing Diabetes: Recent Advances and Future Prospects.International journal of nanomedicine · 2025Review
- Phytoactive Molecules and Nanodelivery Approaches for Breast Cancer Treatment: Current and Future Perspectives.Current pharmaceutical biotechnology · 2025Review
- Ursolic Acid Formulations Effectively Induce Apoptosis and Limit Inflammation in the Psoriasis Models In Vitro.Biomedicines · 2024Article
- Role of ursolic acid in preventing gastrointestinal cancer: recent trends and future perspectives.Frontiers in pharmacology · 2024Review
- Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects.Beilstein journal of nanotechnology · 2024Review
- The Antitumor and Sorafenib-resistant Reversal Effects of Ursolic Acid on Hepatocellular Carcinoma via Targeting ING5.International journal of biological sciences · 2024Article
- Recent Advances in Biomedical Nanotechnology Related to Natural Products.Current pharmaceutical biotechnology · 2024Review
- Ursolic Acid's Alluring Journey: One Triterpenoid vs. Cancer Hallmarks.Molecules (Basel, Switzerland) · 2023Review
- The Promise of Piperine in Cancer Chemoprevention.Cancers · 2023Review
- AHR, a novel inhibitory immune checkpoint receptor, is a potential therapeutic target for chemoresistant glioblastoma.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.